Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

Market Cap	3.24B -20.9%
Revenue (ttm)	574.88M +3.5%
Net Income	156.70M +26.2%
EPS	0.94 +27.0%
Shares Out	166.80M
PE Ratio	20.69
Forward PE	n/a
Dividend	0.20 (1.04%)
Ex-Dividend Date	Jul 10, 2025

Volume	727,261
Average Volume	1,745,489
Open	19.39
Previous Close	19.45
Day's Range	19.16 - 19.57
52-Week Range	17.38 - 31.13
Beta	0.53
RSI	59.78
Earnings Date	Apr 23, 2026

About Cabio Biotech (Wuhan)

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 574
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688089

Financial Performance

In 2025, Cabio Biotech (Wuhan)'s revenue was 574.88 million, an increase of 3.47% compared to the previous year's 555.59 million. Earnings were 156.70 million, an increase of 26.15%.